TEVA Teva- Pharmaceutical Industries Ltd. -
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Company profile
Ticker
TEVA
Exchange
Website
CEO
Kåre Schultz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott • Abbvie • Celgene ...
Former names
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
SEC CIK
Corporate docs
TEVA stock data
()
Calendar
5 Nov 20
5 Dec 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 3 Nov 20 | Kare Schultz | Ordinary Shares | Option exercise | Aquire M | No | 0 | 212,314 | 0 | 482,794 |
| 3 Nov 20 | Kare Schultz | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | 0 | 212,314 | 0 | 0 |
| 1 Nov 20 | Kare Schultz | Ordinary Shares | Option exercise | Aquire M | No | 0 | 180,000 | 0 | 270,480 |
| 1 Nov 20 | Kare Schultz | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | 0 | 180,000 | 0 | 296,389 |
| 9 Sep 20 | Richard Daniell | Ordinary Shares | Sell | Dispose S | Yes | 8.9844 | 333 | 2.99K | 10,765 |
| 9 Sep 20 | Richard Daniell | Ordinary Shares | Option exercise | Aquire M | No | 0 | 698 | 0 | 11,098 |
| 9 Sep 20 | Richard Daniell | Restricted Share Units Ordinary Shares | Option exercise | Dispose M | No | 0 | 698 | 0 | 0 |
| 2 Sep 20 | Abbas Hussain | Restricted Share Units Ordinary Shares | Grant | Aquire A | No | 0 | 13,050 | 0 | 13,050 |
| 11 Aug 20 | Crane Rosemary A | Ordinary Shares | Sell | Dispose S | No | 11.9013 | 2,860 | 34.04K | 33,509 |
| 11 Aug 20 | Crane Rosemary A | Ordinary Shares | Option exercise | Aquire M | No | 0 | 7,956 | 0 | 36,369 |
Institutional ownership Q3 2020
51.1% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 431 |
| Opened positions | 52 |
| Closed positions | 69 |
| Increased positions | 121 |
| Reduced positions | 141 |
13F shares |
Current |
|---|---|
| Total value | 38.3B |
| Total shares | 558.29M |
| Total puts | 18.49M |
| Total calls | 15.04M |
| Total put/call ratio | 1.2 |
Largest owners |
Shares | Value |
|---|---|---|
| Capital Research Global Investors | 130.11M | $1.17B |
| Capital World Investors | 52.81M | $475.78M |
| BRK.A Berkshire Hathaway Inc. - | 42.79M | $385.53M |
| BLK Blackrock | 38.01M | $342.45M |
| Abrams Capital Management | 24.05M | $216.66M |
| Capital International Investors | 23.41M | $210.95M |
| Migdal Insurance & Financial | 17.49M | $157.55M |
| STT State Street | 16.48M | $148.5M |
| Clal Insurance Enterprises | 13.91M | $125.32M |
| Menora Mivtachim | 13.34M | $120.19M |
Financial report summary
?Competition
Akorn • Teligent • Spectrum Pharmaceuticals • Actavis • ARIAD Pharmaceuticals • Nektar Therapeutics • Neurocrine Biosciences • Acorda Therapeutics • Innoviva • NeuBase Therapeutics
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
ActavisGenericsthat, added, adolescent, adult, aforementioned, AirDuo, andproducing, andthose, anincome, Apixaban, Appendix, ArmonAir, Ascorbate, Ascorbic, Atripla, beennamed, Brazilian, breathing, Bystolic, bythe, Canadamay, Carbamazepine, Chloride, Clotrimazole, Committee, conviction, core, Cream, customary, debarment, deceleration, decreesat, Dimethyl, disoproxil, distancing, efavirenz, emtricitabine, en, endpoint, Etodolac, evidence, expensesand, Fluocinonide, fluticasone, gathered, guilty, HIV, holding, hospital, Imiquimod, indicted, indictment, influence, inNovember, intention, judge, krona, lira, magistrate, millionrelated, MoviPrep, Nadolol, nebivolol, negotiate, neuropsychiatry, ofadoption, ofArmonAir, ofSeptember, Ointment, Pa, pled, Potassium, Pravastatin, progression, propionate, proven, Proxy, recommendation, recommended, reconciling, referencedabove, reinstated, relaunch, relieve, restructuringand, salmeterol, Sherman, social, Sodium, strength, Subplan, Subtopic, sudden, sustainability, Swedish, taxexpense, Temozolomide, tenofovir, theearlier, theexpected, timeframe, Tobramycin, Truvada, Turkish, Warfarin, wasapproved, wave, wheezing, Yorkcommenced, Zyclara
Removed:
conform, creditable, epinephrine, injection, IP, lack, Penalty, permitted, permitting, proceeded, producing, receipt, refundable, sector, similarly, situated, stipulated, TriCor
Financial reports
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
21 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19
10-K
2018 FY
Annual report
19 Feb 19
10-Q
2018 Q3
Quarterly report
1 Nov 18
10-Q
2018 Q2
Quarterly report
2 Aug 18
Current reports
8-K
Results of Operations and Financial Condition
5 Nov 20
8-K
Departure of Directors or Certain Officers
6 Aug 20
8-K
Results of Operations and Financial Condition
5 Aug 20
8-K
Departure of Directors or Certain Officers
9 Jun 20
8-K
Results of Operations and Financial Condition
7 May 20
8-K
Results of Operations and Financial Condition
12 Feb 20
8-K
Entry into a Material Definitive Agreement
25 Nov 19
8-K
Departure of Directors or Certain Officers
7 Nov 19
8-K
Results of Operations and Financial Condition
7 Nov 19
8-K
Regulation FD Disclosure
23 Oct 19
Registration and prospectus
424B3
Prospectus supplement
17 Aug 20
S-4
Registration of securities issued in business combination transactions
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Aug 20
S-8
Registration of securities for employees
5 Aug 20
F-6
Registration for ADRs (foreign)
13 Nov 18
424B3
Prospectus supplement
19 Apr 18
Proxies
DEFA14A
Additional proxy soliciting materials
26 May 20
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
PRE 14A
Preliminary proxy
19 Mar 20
DEFA14A
Additional proxy soliciting materials
16 Apr 19
DEF 14A
Definitive proxy
16 Apr 19
DEF 14A
Definitive proxy
25 Apr 18
DEFA14A
Additional proxy soliciting materials
25 Apr 18
Other
EFFECT
Notice of effectiveness
18 Aug 20
SD
Conflict minerals disclosure
14 Aug 20
CORRESP
Correspondence with SEC
13 Aug 20
CORRESP
Correspondence with SEC
13 Aug 20
UPLOAD
Letter from SEC
11 Aug 20
UPLOAD
Letter from SEC
15 Jul 20
CORRESP
Correspondence with SEC
19 Jun 20
CORRESP
Correspondence with SEC
17 Apr 20
SD
Conflict minerals disclosure
31 May 19
EFFECT
Notice of effectiveness
4 Dec 18
Ownership
4
TEVA PHARMACEUTICAL INDUSTRIES / Kare Schultz ownership change
3 Nov 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Richard Daniell ownership change
10 Sep 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Abbas Hussain ownership change
3 Sep 20
3
TEVA PHARMACEUTICAL INDUSTRIES / Abbas Hussain ownership change
3 Sep 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Nechemia Jacob Peres ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Perry Nisen ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / ROBERTO MIGNONE ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / GERALD M LIEBERMAN ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Jean Michel Halfon ownership change
13 Aug 20
4
TEVA PHARMACEUTICAL INDUSTRIES / Amir Elstein ownership change
13 Aug 20
Patents
APP
Utility
Pre-filled Syringe
3 Dec 20
The invention relates to a pre-filled syringe, an auto-injector device comprising such pre-filled syringe, a method of administering a pharmaceutical composition with such auto-injector device, and a manufacturing method for such auto-injector device.
APP
Utility
Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same
3 Dec 20
The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody.
APP
Utility
Drug Delivery Device with Electronics
19 Nov 20
A system may include an external device and an inhaler.
GRANT
Utility
Pre-filled syringe
17 Nov 20
The invention relates to a pre-filled syringe, an auto-injector device comprising such pre-filled syringe, a method of administering a pharmaceutical composition with such auto-injector device, and a manufacturing method for such auto-injector device.
APP
Utility
Inhaler System
5 Nov 20
Provided is a system (10) for determining a probability of an asthma exacerbation in a subject.